Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
1-15 of 4212 results
Pfizer's breast cancer drug improves progression-free survival in Phase 3 trial
Pfizer announced that talazoparib has improved progression-free survival (PFS) in patients with germline (inherited) BRCA1/2-positive (gBRCA+) locally advanced or metastatic breast cancer (MBC) in the Phase 3 Embraca study.
Contract Research & Services > Clinical Trials > News
Lilly’s Cyramza meets primary endpoint in phase 3 gastric cancer trial
By PBR Staff Writer
Eli Lilly and Company’s (Lilly) phase 3 trial of Cyramza (ramucirumab) for the treatment of a type of gastric cancer was a mixed bag as it met its primary objective of preventing the condition from advancing but could not improve overall survival (OS).
Contract Research & Services > Clinical Trials > News
Roche’s lung cancer drug combo study shows improvement in progression-free survival
By PBR Staff Writer
Roche has announced that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) has extended the life of patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC) in the Phase III IMpower150 study.
Contract Research & Services > Clinical Trials > News
Novartis' Kisqali improves PFS in younger women with advanced breast cancer
By PBR Staff Writer
Results from a phase 3 clinical trial evaluating Novartis' Kisqali (ribociclib) in premenopausal women with HR+/HER2- advanced/metastatic breast cancer demonstrated a significant treatment benefit.
Contract Research & Services > Clinical Trials > News
Janssen’s Imbruvica- rituximab combination meets primary end point in phase 3 study
By PBR Staff Writer
Janssen Research & Development (Janssen) has announced that the combination of Imbruvica (ibrutinib) and rituximab (Rituxan) has improved progression-free survival (PFS) in patients with Waldenstrom macroglobulinemia (WM) in the Phase 3 iNNOVATE (PCYC-1127) study.
Contract Research & Services > Clinical Trials > News
Realm Therapeutics doses first patient in phase 2 study of PR022 to treat atopic dermatitis
Realm Therapeutics announced that the first patient has been dosed in its Phase 2 study of PR022, the Company's proprietary topical gel formulation of high concentration hypochlorous acid, for the treatment of atopic dermatitis.
Contract Research & Services > Clinical Trials > News
AbbVie’s risankizumab meets all primary endpoints in fourth phase 3 psoriasis trial
By PBR Staff Writer
AbbVie’s psoriasis drug risankizumab (150 mg) has met all the primary endpoints in the two phases of a fourth pivotal phase 3 clinical trial in patients with moderate to severe plaque psoriasis.
Contract Research & Services > Clinical Trials > News
NIH and partners commence HIV vaccine efficacy trial
The National Institutes of Health (NIH) and partners have started a clinical trial to evaluate whether an experimental HIV vaccine regimen is safe and effective in prevention of HIV infection.
Contract Research & Services > Clinical Trials > News
Revance Therapeutics plans phase 3 program for RT002 injectable to treat cervical dystonia
Revance Therapeutics has completed its End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) and has received scientific advice from the Europe Medicines Agency (EMA) regarding DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia.
Contract Research & Services > Clinical Trials > News
Novartis and Amgen’s erenumab succeeds in phase 3 episodic migraine trial
By PBR Staff Writer
Novartis and Amgen’s human monoclonal antibody erenumab has succeeded in a phase 3 study by demonstrating significant and sustained efficacy in the prevention of episodic migraine.
Contract Research & Services > Clinical Trials > News
Viking’s VK5211 meets primary endpoint in phase 2 hip fracture trial
By PBR Staff Writer
Viking Therapeutics’ hip fracture treatment VK5211 has met primary endpoint in a 12-week phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
Takeda starts phase 1 trial of Zika virus vaccine candidate
By PBR Staff Writer
Japan's Takeda Pharmaceutical has started a phase 1 clinical trial of its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate, TAK-426.
Contract Research & Services > Clinical Trials > News
Biothera signs cancer immunotherapy clinical trial collaboration deal with Genentech
Biothera Pharmaceuticals has entered into a clinical trial collaboration agreement with Genentech to assess the safety and efficacy of Biothera’s Imprime PGG in combination with Genentech’s atezolizumab (TECENTRIQ), an anti-PD-L1 antibody, and bevacizumab (AVASTIN), an anti-VEGF antibody, to treat patients with metastatic colorectal cancer.
Contract Research & Services > Clinical Trials > News
Regeneron’s eye-drug combination fails in two Phase 2 studies
By PBR Staff Writer
Regeneron Pharmaceuticals announced that results from two Phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to EYLEA (aflibercept) Injection did not provide enough differentiation to warrant phase 3 development.
Contract Research & Services > Clinical Trials > News
ViiV Healthcare begins third phase III HIV trial of cabotegravir/rilpivirine regimen
ViiV Healthcare, a joint venture of GSK, Pfizer and Shionogi, has commenced a phase III study with a two-drug regimen of its long-acting, injectable cabotegravir and Janssen Sciences Ireland’s long-acting injectable rilpivirine in virally suppressed adults with HIV-1 infection.
Contract Research & Services > Clinical Trials > News
1-15 of 4212 results